← Leaderboards
John Guatelli
Veterans Medical Research Fdn/San Diego
$21,581,148
Attributed
$26,824,288
Total exposure
25
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,824,288 · 25
By mechanism
R01$14,148,604 · 5
R37$4,784,880 · 1
T32$3,195,069 · 1
R21$2,541,780 · 7
R33$1,195,121 · 1
R56$538,606 · 1
Top collaborators
- Xiaofei Jia7 shared
- Douglas D Richman7 shared
- Rudi Fasan5 shared
- Yong Xiong5 shared
- Sara Gianella Weibel1 shared
- Scott L Letendre1 shared
- Charlotte A Stoneham1 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsHiv-1ProteinsViralVirusMediatingVirionComplexCell MembraneCell SurfaceDown-RegulationCytoplasmic TailBaseIntegral Membrane ProteinSiteT-LymphocyteVirus ReplicationClathrin AdaptorsStructureInfectionDesignTranscription Factor Ap-1Public Health RelevanceTrafficking
Grant awards (78)
Developing Cyclopeptide Nef Inhibitors to Facilitate HIV-1 Eradication$647,861
R01 · FY2025 · AI
Basis of Serinc-Independent Enhancement of Infectivity by HIV-1Nef$214,613
R21 · FY2025 · AI · contact PI
Developing Cyclopeptide Nef Inhibitors to Facilitate HIV-1 Eradication$655,537
R01 · FY2024 · AI
Developing Cyclopeptide Nef Inhibitors to Facilitate HIV-1 Eradication$45,270
R01 · FY2024 · AI
Developing Cyclopeptide Nef Inhibitors to Facilitate HIV-1 Eradication$701,761
R01 · FY2023 · AI
HIV-1 Vpu and BST-2/CD317$510,019
R37 · FY2023 · AI · contact PI
Developing Cyclopeptide Nef Inhibitors to Facilitate HIV-1 Eradication$538,606
R56 · FY2022 · AI
HIV-1 Vpu and BST-2/CD317$510,019
R37 · FY2022 · AI · contact PI
Enhancement of Infectivity by HIV-1 Nef via Antagonism of SERINC Proteins$546,625
R01 · FY2021 · AI · contact PI
HIV-1 Vpu and BST-2/CD317$510,019
R37 · FY2021 · AI · contact PI
HOPE Training Grant$477,166
T32 · FY2021 · AI
High-Throughput Screening for Multifunctional Nef Inhibitors: Targeting HIV through Revitalizing Immune Defense Mechanisms$225,600
R21 · FY2021 · AI
Enhancement of Infectivity by HIV-1 Nef via Antagonism of SERINC Proteins$555,497
R01 · FY2020 · AI · contact PI
HIV-1 Vpu and BST-2/CD317$510,019
R37 · FY2020 · AI · contact PI
AIDS Training Grant$417,874
T32 · FY2020 · AI · contact PI
Activating Latently Infected Cells Using Specific Antigens Including Those of HIV-1$399,707
R33 · FY2020 · AI · contact PI
High-Throughput Screening for Multifunctional Nef Inhibitors: Targeting HIV through Revitalizing Immune Defense Mechanisms$200,600
R21 · FY2020 · AI
Enhancement of Infectivity by HIV-1 Nef via Antagonism of SERINC Proteins$566,104
R01 · FY2019 · AI · contact PI
HIV-1 Vpu and BST-2/CD317$510,019
R37 · FY2019 · AI · contact PI
Activating Latently Infected Cells Using Specific Antigens Including Those of HIV-1$399,275
R33 · FY2019 · AI · contact PI
AIDS Training Grant$379,416
T32 · FY2019 · AI · contact PI
Enhancement of Infectivity by HIV-1 Nef via Antagonism of SERINC Proteins$573,926
R01 · FY2018 · AI · contact PI
HIV-1 Vpu and BST-2/CD317$446,957
R37 · FY2018 · AI · contact PI
Activating Latently Infected Cells Using Specific Antigens Including Those of HIV-1$396,139
R33 · FY2018 · AI · contact PI
AIDS Training Grant$358,507
T32 · FY2018 · AI · contact PI
Viral Hijacking of Host Membrane Trafficking Pathways$611,999
R01 · FY2017 · AI
Enhancement of Infectivity by HIV-1 Nef via Antagonism of SERINC Proteins$600,097
R01 · FY2017 · AI · contact PI
HIV-1 Vpu and BST-2/CD317$446,957
R37 · FY2017 · AI · contact PI
AIDS Training Grant$413,341
T32 · FY2017 · AI · contact PI
Activating Latently Infected Cells Using Specific Antigens Including Those of HIV-1$178,750
R21 · FY2017 · AI · contact PI
Viral Hijacking of Host Membrane Trafficking Pathways$611,999
R01 · FY2016 · AI
HIV-1 Vpu and BST-2/CD317$446,957
R37 · FY2016 · AI · contact PI
AIDS Training Grant$436,277
T32 · FY2016 · AI · contact PI
Activating Latently Infected Cells Using Specific Antigens Including Those of HIV-1$214,500
R21 · FY2016 · AI · contact PI
Viral Hijacking of Host Membrane Trafficking Pathways$611,999
R01 · FY2015 · AI
HIV-1 Vpu and BST-2/CD317$446,957
R37 · FY2015 · AI · contact PI
AIDS Training Grant$392,792
T32 · FY2015 · AI
Inhibiting Immune Evasion by HIV-1 Nef to Facilitate Eradication$189,015
R21 · FY2015 · AI · contact PI
Involvement of the C-terminus of HIV-1 Vpu in Enhancement of Virion Release$174,000
R21 · FY2015 · AI · contact PI
Viral Hijacking of Host Membrane Trafficking Pathways$611,999
R01 · FY2014 · AI
HIV-1 Vpu and BST-2/CD317$446,957
R37 · FY2014 · AI · contact PI
AIDS Training Grant$319,696
T32 · FY2014 · AI
Inhibiting Immune Evasion by HIV-1 Nef to Facilitate Eradication$236,345
R21 · FY2014 · AI · contact PI
Involvement of the C-terminus of HIV-1 Vpu in Enhancement of Virion Release$208,800
R21 · FY2014 · AI · contact PI
Viral Hijacking of Host Membrane Trafficking Pathways$591,301
R01 · FY2013 · AI
HIV 1 Nef and Viral Infectivity$355,942
R01 · FY2013 · AI · contact PI
HIV-1 Vpu and BST-2/CD317$326,139
R01 · FY2013 · AI · contact PI
HIV 1 Nef and Viral Infectivity$378,663
R01 · FY2012 · AI · contact PI
HIV-1 Vpu and BST-2/CD317$346,955
R01 · FY2012 · AI · contact PI
HIV 1 Nef and Viral Infectivity$378,663
R01 · FY2011 · AI · contact PI
HIV-1 Vpu and BST-2/CD317$346,955
R01 · FY2011 · AI · contact PI
ULTRASTRUCTURAL LOCALIZATION OF THE HOST ANTIVIRAL PROTEIN BST-2$66,058
P41 · FY2011 · RR · contact PI
HIV 1 Nef and Viral Infectivity$392,887
R01 · FY2010 · AI · contact PI
HIV-1 Vpu and BST-2/CD317$350,460
R01 · FY2010 · AI · contact PI
HIV-1 Vpu and BST-2/CD317$86,776
R01 · FY2010 · AI · contact PI
ULTRASTRUCTURAL LOCALIZATION OF THE HOST ANTIVIRAL PROTEIN BST-2$36,406
P41 · FY2010 · RR · contact PI
HIV-1 Vpu and BST-2/CD317$354,000
R01 · FY2009 · AI · contact PI
HIV-1 Vpu and BST-2/CD317$299,348
R01 · FY2009 · AI · contact PI
ULTRASTRUCTURAL LOCALIZATION OF THE HOST ANTIVIRAL PROTEIN BST-2$47,707
P41 · FY2009 · RR · contact PI
IN VITRO STUDIES OF HIV IN PRIMARY CULTURES OF HUMAN BLOOD CELLS$39,219
M01 · FY2009 · RR · contact PI
HIV 1 Nef and Viral Infectivity$365,740
R01 · FY2008 · AI · contact PI
The MHC-I, HIV-1 Nef, AP-1 Complex$202,185
R21 · FY2008 · AI · contact PI
IN VITRO STUDIES OF HIV NEF IN PRIMARY CULTURES OF HUMAN T CELLS$24,693
M01 · FY2008 · RR · contact PI
HIV 1 Nef and Viral Infectivity$365,000
R01 · FY2007 · AI · contact PI
The MHC-I, HIV-1 Nef, AP-1 Complex$166,872
R21 · FY2007 · AI · contact PI
IN VITRO STUDIES OF HIV NEF IN PRIMARY CULTURES OF HUMAN T CELLS$8,364
M01 · FY2007 · RR · contact PI
HIV 1 Nef and Viral Infectivity$368,076
R01 · FY2006 · AI · contact PI
INDUCTION OF T CELL ACTIVATION & POLARIZATION: HIV$33,605
P41 · FY2006 · RR · contact PI
IN VITRO STUDIES OF HIV HEF IN PRIMARY CULTURES OF HUMAN T CELLS$9,121
M01 · FY2006 · RR · contact PI
HIV 1 Nef and Viral Infectivity$369,154
R01 · FY2005 · AI
INDUCTION OF T CELL ACTIVATION &POLARIZATION: HIV$59,031
P41 · FY2005 · RR
IN VITRO STUDIES OF HIV HEF IN PRIMARY CULTURES OF HUMAN T CELLS$781
M01 · FY2005 · RR
HIV 1 Nef and Viral Infectivity$242,465
R01 · FY2004 · AI
INDUCTION OF T CELL ACTIVATION &POLARIZATION: HIV$95,243
P41 · FY2004 · RR
HIV 1 NEF and Infectivity$330,500
R21 · FY2003 · AI
HIV 1 NEF AND VIRAL INFECTIVITY$354,530
R01 · FY2002 · AI
HIV 1 NEF AND VIRAL INFECTIVITY$271,390
R01 · FY2001 · AI
HIV 1 NEF AND VIRAL INFECTIVITY$263,486
R01 · FY2000 · AI